Hope Bancorp (HOPE) Stock

Hope Bancorp, Inc. (NASDAQ:HOPE ) Q3 2024 Earnings Conference Call October 28, 2024 12:30 PM ET Company Participants Angie Yang - Director of Investor Relations Kevin Kim - Chairman, President and Chief Executive Officer Julianna Balicka - Executive Vice President and Chief Financial Officer Peter Koh - Senior Executive Vice President and Chief Operating Officer Conference Call Participants Gary Tenner - D.A. Davidson Christopher McGratty - KBW Matthew Clark - Piper Sandler Operator Good day and welcome to the Hope Bancorp 2024 Third Quarter Earnings Conference Call.

Although the revenue and EPS for Hope Bancorp (HOPE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Hope Bancorp (HOPE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

-Data Supports Deramiocel's Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle Function Over 3 Years of Treatment- -Company on Track to Fully Submit Biologics License Application (BLA) by End of 2024- SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive 3-year safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study for its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). The data was highlighted in a late-breaking poster presentation at the 29th Annual Congress of the World Muscle Society (WMS), October 8-12, 2024 in Prague, Czechia.

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that the Company will present the three-year safety and efficacy results from its HOPE-2 open-label extension (OLE) study with lead asset deramiocel for treating Duchenne muscular dystrophy (DMD). The data will highlight the long-term, multi-modal benefits of deramiocel in a late-breaking poster presentation at the 29th Annual Congress of the World Muscle Society (WMS 2024), taking place October 8-12, 2024, in Prague, Czechia.

Free financial counseling expands in Kentucky one year after the launch of mobile sports betting Partnership with leading organization dedicated to providing access to financial education and empowerment aims to help individuals understand how to best manage their personal finances for long-term financial security NEW YORK , Sept. 17, 2024 /PRNewswire/ -- FanDuel, the premier online gaming company in North America, today announced a second $1 million donation to Operation HOPE, the nation's leading non-profit dedicated to financial literacy, to promote financial empowerment and expand access to free financial counseling to residents of Kentucky.

Hope Bancorp, Inc. (NASDAQ:HOPE ) Q2 2024 Earnings Call Transcript July 29, 2024 12:30 PM ET Company Participants Angie Yang - Director of IR Kevin Kim - Chairman, President, and CEO Julianna Balicka - CFO Conference Call Participants Matthew Clark - Piper Sandler Chris McGratty - KBW Gary Tenner - D.A. Davidson Operator Good day, and welcome to the Hope Bancorp 2024 Second Quarter Earnings Conference Call.

Capricor Therapeutics, Inc.'s rolling BLA submission of CAP-1002 for the treatment of patients with DMD, expected in Q3 of 2024. Top-line results from Cohort A of the phase 3 HOPE-3 study, using CAP-1002 for the treatment of patients with DMD, expected Q4 of 2024. Additional results from phase 2 HOPE-2 study, using CAP-1002 for patients with DMD, to be presented at the upcoming PPMD 30th Annual conference between June 27th - 29th of 2024.

Hope Bancorp (HOPE) reported quarterly earnings of $0.23 per share, falling short of the Zacks Consensus Estimate of $0.27 per share. This is lower than the earnings of $0.33 per share from the same quarter last year.